Literature DB >> 18284275

Treatment strategies to prevent relapse and encourage remission.

John M Kane1.   

Abstract

Remission is a realistic goal for patients with schizophrenia, and, if sustained remission without relapse can be achieved, then patients may attain functional recovery. With each relapse, recovery can be slowed and the course of illness worsened. The risk of self-harm and harm to others increases with each psychotic episode. The chance of relapse is decreased if pharmacotherapy continues uninterrupted, and one strategy to ensure continuous treatment is using long-acting injectable antipsychotic medications. Achieving remission of schizophrenia is clinically meaningful because, besides symptom control, remission allows for improved vocational and social functioning. Functional recovery without relapse allows patients to return to work, sustain interpersonal relationships, and lead more productive lives. Therefore, achieving the goals of remission and recovery is in the best interest not only of patients with schizophrenia but also of society.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 18284275

Source DB:  PubMed          Journal:  J Clin Psychiatry        ISSN: 0160-6689            Impact factor:   4.384


  35 in total

1.  The revolving door phenomenon in psychiatry: comparing low-frequency and high-frequency users of psychiatric inpatient services in a developing country.

Authors:  Ulla A Botha; Liezl Koen; John A Joska; John S Parker; Neil Horn; Linda M Hering; Piet P Oosthuizen
Journal:  Soc Psychiatry Psychiatr Epidemiol       Date:  2009-06-18       Impact factor: 4.328

2.  Ethical considerations when treating patients with schizophrenia.

Authors:  Edmund Howe
Journal:  Psychiatry (Edgmont)       Date:  2008-04

3.  Rates and predictors of relapse in first-episode non-affective psychosis: a 3-year longitudinal study in a specialized intervention program (PAFIP).

Authors:  José María Pelayo-Terán; Virginia Gajardo Gajardo Galán; Víctor de la Ortiz-García de la Foz; Obdulia Martínez-García; Rafael Tabarés-Seisdedos; Benedicto Crespo-Facorro; Rosa Ayesa-Arriola
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2016-10-28       Impact factor: 5.270

4.  Molecular Features Triggered by Antipsychotic Medication in Brain Cells.

Authors:  Lívia Ramos-da-Silva; André S L M Antunes
Journal:  Adv Exp Med Biol       Date:  2022       Impact factor: 3.650

5.  Real-World Utilization Patterns of Long-Acting Injectable Antipsychotics in Canada: A Retrospective Study.

Authors:  Ofer Agid; Gary Remington; Carmen Fung; Natalie M Nightingale; Marc Duclos; Gregory J Anger
Journal:  Can J Psychiatry       Date:  2021-11-18       Impact factor: 5.321

6.  Lifetime relapse and its associated factors among people with schizophrenia spectrum disorders who are on follow up at Comprehensive Specialized Hospitals in Amhara region, Ethiopia: a cross-sectional study.

Authors:  Solomon Moges; Tilahun Belete; Tesfa Mekonen; Melak Menberu
Journal:  Int J Ment Health Syst       Date:  2021-05-06

7.  Predictors of persistence in patients with schizophrenia treated with aripiprazole once-monthly long-acting injection in the Spanish clinical practice: a retrospective, observational study.

Authors:  José Manuel Olivares; Ana González-Pinto; Mario Páramo
Journal:  Eur Psychiatry       Date:  2021-04-12       Impact factor: 5.361

8.  Chronic treatment with aripiprazole prevents development of dopamine supersensitivity and potentially supersensitivity psychosis.

Authors:  Shigenori Tadokoro; Naoe Okamura; Yoshimoto Sekine; Nobuhisa Kanahara; Kenji Hashimoto; Masaomi Iyo
Journal:  Schizophr Bull       Date:  2011-03-14       Impact factor: 9.306

9.  A one-year prospective study of the safety, tolerability and pharmacokinetics of the highest available dose of paliperidone palmitate in patients with schizophrenia.

Authors:  Danielle Coppola; Yanning Liu; Srihari Gopal; Bart Remmerie; Mahesh N Samtani; David W Hough; Isaac Nuamah; Ahmad Sulaiman; Gahan Pandina
Journal:  BMC Psychiatry       Date:  2012-03-28       Impact factor: 3.630

Review 10.  The nature of relapse in schizophrenia.

Authors:  Robin Emsley; Bonginkosi Chiliza; Laila Asmal; Brian H Harvey
Journal:  BMC Psychiatry       Date:  2013-02-08       Impact factor: 3.630

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.